Webinar: New Developments in Prostate Cancer Radioligand Therapies and How to Access Them!
Pluvicto has established radioligand therapy (RLT) as a highly viable treatment for Prostate Cancer. But it’s just the tip of the iceberg when it comes to RLT options and when to use them.
Welcome experts Dr. Michael Hofman and Dr. Frankis Almaguel to address what’s novel and when patients can expect access. Dr. Hofman will cover new developments, and Dr. Almaguel will discuss clinical trials. Both will consider when RLT may come to non-metastatic men. This event was hosted by Cdr. Mike Crosby, Director of the Oncidium Foundation.
Click here for Dr. Michael Hofman’s presentation slides.
